Pontifax

Investor type Venture Capital
Founders Ran Nussbaum Tomer Kariv

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 86
Average round size
info
The average size of a deal this fund participated in
$32M
Portfolio companies 60
Rounds per year 5.06
Lead investments 13
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.30
Exits 25
Key employees 5
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Medical
  • Pharmaceutical
  • Therapeutics
Summary

Pontifax appeared to be the VC, which was created in 2004. The main department of described VC is located in the Herzliya. The fund was located in Asia if to be more exact in Israel.

The important activity for fund was in 2017. The usual things for fund are deals in the range of 10 - 50 millions dollars. Speaking about the real fund results, this VC is 7 percentage points more often commits exit comparing to other organizations. Comparing to the other companies, this Pontifax performs on 4 percentage points less the average number of lead investments. The fund is generally included in 2-6 deals every year. The increased amount of exits for fund were in 2019.

For fund there is a match between the country of its foundation and the country of its the most frequent investments - Israel. The fund has specific favorite in a number of founders of portfolio startups. In case when startup counts 4 of the founder, the chance for it to get the investment is meager. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight 89bio, Dynacure, Check-Cap. Among the most successful fund investment fields, there are Pharmaceutical, Health Care.

This organization was formed by Ran Nussbaum, Tomer Kariv. The overall number of key employees were 10.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Pontifax, startups are often financed by OrbiMed, Ziegler Meditech Equity Partners, Perceptive Advisors. The meaningful sponsors for the fund in investment in the same round are Docor International Management, Quark Venture, Triventures. In the next rounds fund is usually obtained by Yissum Technology Transfer Company of the Hebrew University, Docor International Management, Clal Biotechnology Industries.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Pontifax:
Typical Co-investors
Pontifax is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Pontifax:

Funds with similar focus

Funds from Israel
Funds with similar focus located in Israel:
Funds with the same geo focus
Funds with similar geography of portfolio companies:
Funds doing lead investments
Funds with similar focus acting as lead investors:

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Emergence Therapeutics

Fitness
Health Care
Wellness
$102M07 Dec 2021 Duisburg, Nordrhein-Westfalen, Germany

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
$75M03 Nov 2021 Atlanta, Georgia, United States

Amolyt Pharma

Health Care
Medical
Therapeutics
$80M16 Sep 2021 Écully, Rhone-Alpes, France

Biotechnology
Health Care
Information Technology
Pharmaceutical
Travel
$100M13 Apr 2021 New York, New York, United States

Antios Therapeutics

Biopharma
Biotechnology
Therapeutics
$96M12 Apr 2021 Atlanta, Georgia, United States

Step Pharma

Biotechnology
Pharmaceutical
$41M24 Mar 2021 Paris, Ile-de-France, France

StrideBio

Biotechnology
Health Care
Information Technology
Therapeutics
$81M16 Mar 2021 Durham, North Carolina, United States

Health Care
Medical
Medical Device
$25M15 Mar 2021 Jerusalem, Jerusalem District, Israel

AgomAb Therapeutics

Biotechnology
Health Care
Therapeutics
$74M10 Mar 2021 East Flanders
News
Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Amolyt Pharma Raises $80M in Series B Financing

– Amolyt Pharma from Lyon develops therapeutic peptides for rare endocrine and related diseases.
– The company closed an $80m Series B round.
– The round was co-led by Sectoral Asset Management and Andera Partners, with participation from ATEM Capital, LSP, Novo Holdings (Novo Ventures), Kurma Partners, Mass General Brigham Ventures, Innobio 2 managed by Bpifrance, Orbimed, Pontifax, Eurazeo, Sham Innovation Santé/Turenne Capital and Credit Agricole Creation.
– The company plans to use the proceeds from the financing to advance its pipeline of potential therapeutics for rare endocrine and related diseases, including clinical development of AZP-3601 for hypoparathyroidism, pre-clinical development of AZP-3813 for acromegaly and ongoing research related to AZP-3404, and to further expand its early-stage pipeline through both internal research and development activities and potential in-licensing opportunities.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Pontifax?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: